

Title (en)  
COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION

Title (de)  
ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON HYPERTONIE

Title (fr)  
COMPOSITIONS POUR LE TRAITEMENT DE L'HYPERTENSION

Publication  
**EP 3826633 A4 20220427 (EN)**

Application  
**EP 19841262 A 20190726**

Priority  
• US 201862703802 P 20180726  
• IB 2019000923 W 20190726

Abstract (en)  
[origin: US2020030296A1] Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

IPC 8 full level  
**A61K 31/4184** (2006.01); **A61K 31/18** (2006.01); **A61K 31/277** (2006.01); **A61K 31/341** (2006.01); **A61K 31/382** (2006.01); **A61K 31/397** (2006.01); **A61K 31/40** (2006.01); **A61K 31/4035** (2006.01); **A61K 31/404** (2006.01); **A61K 31/41** (2006.01); **A61K 31/4178** (2006.01); **A61K 31/4245** (2006.01); **A61K 31/4422** (2006.01); **A61K 31/445** (2006.01); **A61K 31/47** (2006.01); **A61K 31/495** (2006.01); **A61K 31/505** (2006.01); **A61K 31/517** (2006.01); **A61K 31/554** (2006.01); **A61P 3/06** (2006.01); **A61P 9/12** (2006.01)

CPC (source: AU EP KR US)  
**A61K 31/366** (2013.01 - AU); **A61K 31/397** (2013.01 - AU EP KR US); **A61K 31/4035** (2013.01 - AU); **A61K 31/404** (2013.01 - AU EP US); **A61K 31/4045** (2013.01 - KR); **A61K 31/4178** (2013.01 - AU); **A61K 31/4184** (2013.01 - AU EP KR US); **A61K 31/4418** (2013.01 - EP US); **A61K 31/4422** (2013.01 - AU KR); **A61K 31/505** (2013.01 - AU EP KR US); **A61K 31/549** (2013.01 - AU); **A61K 45/06** (2013.01 - KR); **A61P 3/06** (2018.01 - AU KR); **A61P 9/12** (2018.01 - AU EP KR US); **A61K 9/0019** (2013.01 - EP); **A61K 9/06** (2013.01 - EP); **A61K 9/20** (2013.01 - US); **A61K 9/48** (2013.01 - US); **A61K 47/38** (2013.01 - EP); **A61K 2300/00** (2013.01 - KR)

C-Set (source: AU)  
1. **A61K 31/404 + A61K 2300/00**  
2. **A61K 31/505 + A61K 2300/00**  
3. **A61K 31/366 + A61K 2300/00**  
4. **A61K 31/4422 + A61K 2300/00**  
5. **A61K 31/4178 + A61K 2300/00**  
6. **A61K 31/549 + A61K 2300/00**  
7. **A61K 31/4035 + A61K 2300/00**  
8. **A61K 31/4184 + A61K 2300/00**  
9. **A61K 31/397 + A61K 2300/00**

Citation (search report)  
• [Y] CN 101618215 A 20100106 - LIYAN WANG  
• [Y] KR 20090057538 A 20090608 - PARK SA RYONG [KR]  
• [Y] ANONYMOUS 1: "ASSESSMENT REPORT FOR Exforge HCT", 1 January 2009 (2009-01-01), Internet, pages 1 - 45, XP055902031, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/documents/assessment-report/exforge-hct-epar-public-assessment-report\_en.pdf>  
• [A] FLETCHER ET AL: "Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke", AMERICAN JOURNAL OF CARDIOLOGY, CAHNSERS PUBLISHING CO., NEWTON, MA, US, vol. 99, no. 6, 20 March 2007 (2007-03-20), pages S1 - S35, XP022008050, ISSN: 0002-9149, DOI: 10.1016/J.AMJCARD.2007.02.001  
• See also references of WO 2020021341A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**US 2020030296 A1 20200130**; AU 2019309329 A1 20210311; BR 112021001374 A2 20210706; CA 3107616 A1 20200130; CN 112770746 A 20210507; EP 3826633 A1 20210602; EP 3826633 A4 20220427; JP 2022511588 A 20220201; JP 7474738 B2 20240425; KR 20210038931 A 20210408; MX 2021001043 A 20210412; US 2023125076 A1 20230427; WO 2020021341 A1 20200130; WO 2020021341 A8 20210318; ZA 202006591 B 20210825

DOCDB simple family (application)  
**US 201916523230 A 20190726**; AU 2019309329 A 20190726; BR 112021001374 A 20190726; CA 3107616 A 20190726; CN 201980063218 A 20190726; EP 19841262 A 20190726; IB 2019000923 W 20190726; JP 2021504441 A 20190726; KR 20217005757 A 20190726; MX 2021001043 A 20190726; US 202218067335 A 20221216; ZA 202006591 A 20201022